- Home
- RLAY
as 01-21-2025 4:00pm EST
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 723.1M | IPO Year: | 2020 |
| Target Price: | $20.11 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.50 - $11.16 | Next Earning Date: | 02-20-2025 |
| Revenue: | $10,006,000 | Revenue Growth: | -61.22% |
| Revenue Growth (this year): | -37.95% | Revenue Growth (next year): | -77.38% |
Stock Insider Trading Activity of Relay Therapeutics Inc. (RLAY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rahmer Peter | RLAY | See remarks | Jan 2 '25 | Sell | $4.30 | 80,909 | $345,571.70 | 357,507 | |
| Bergstrom Donald A | RLAY | President, R&D | Dec 27 '24 | Sell | $4.38 | 657 | $2,877.66 | 520,088 | |
| Catinazzo Thomas | RLAY | Chief Financial Officer | Dec 27 '24 | Sell | $4.40 | 4,865 | $21,491.34 | 303,792 | |
| Rahmer Peter | RLAY | See remarks | Dec 27 '24 | Sell | $4.38 | 400 | $1,752.00 | 357,507 | |
| Patel Sanjiv | RLAY | President and CEO | Dec 16 '24 | Sell | $5.00 | 100,000 | $500,000.00 | 574,548 | |
| Bergstrom Donald A | RLAY | President, R&D | Oct 28 '24 | Sell | $6.06 | 2,688 | $16,289.28 | 520,088 | |
| Adams Brian | RLAY | Chief Legal Officer | Oct 28 '24 | Sell | $6.06 | 1,632 | $9,889.92 | 321,907 | |
| Catinazzo Thomas | RLAY | Chief Financial Officer | Oct 28 '24 | Sell | $6.02 | 9,102 | $54,905.12 | 303,792 | |
| Rahmer Peter | RLAY | See remarks | Oct 28 '24 | Sell | $6.06 | 1,621 | $9,823.26 | 357,507 |
Latest Relay Therapeutics Inc. News
RLAY Breaking Stock News: Dive into RLAY Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 days ago
We're Keeping An Eye On Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate
GlobeNewswire
15 days ago
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Insider Monkey
23 days ago
Is Relay Therapeutics (RLAY) the Best Biotech Penny Stock to Invest in Now?
Zacks
a month ago
Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the Upgrade
MT Newswires
a month ago
Relay Therapeutics Insider Sold Shares Worth $500,000, According to a Recent SEC Filing
Insider Monkey
a month ago
Relay Therapeutics, Inc. (RLAY): A Bull Case Theory
MT Newswires
a month ago
Relay Therapeutics Says RLY-2608 With Fulvestrant Data Shows 'Clinically Meaninful' Metastatic Breast Cancer Survival
GlobeNewswire
a month ago
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
Compare RLAY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RLAY Relay Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.